Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Arena Pharmaceuticals, Inc.    ARNA

ARENA PHARMACEUTICALS, INC.

(ARNA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/15/2021 01/19/2021 01/20/2021 01/21/2021 01/22/2021 Date
80.5(c) 80.7(c) 81.22(c) 76.66(c) 77.68(c) Last
471 294 620 506 468 194 456 456 480 902 Volume
-0.07% +0.25% +0.64% -5.61% +1.33% Change
More quotes
Financials (USD)
Sales 2020 0,74 M - -
Net income 2020 -390 M - -
Net cash position 2020 828 M - -
P/E ratio 2020 -10,9x
Yield 2020 -
Sales 2021 26,5 M - -
Net income 2021 -453 M - -
Net cash position 2021 575 M - -
P/E ratio 2021 -10,3x
Yield 2021 -
Capitalization 4 518 M 4 518 M -
EV / Sales 2020 4 973x
EV / Sales 2021 149x
Nbr of Employees 320
Free-Float 98,7%
More Financials
Company
Arena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn's disease, and ralinepag (APD811) in Phase II... 
More about the company
Notations Surperformance© of Arena Pharmaceuticals, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about ARENA PHARMACEUTICALS, INC.
01/22ARENA PHARMACEUTICALS : Reports Inducement Grants Under Nasdaq Listing Rule 5635..
BU
01/20INSIDER TRENDS : Arena Pharmaceuticals Sees 90 Days of Insider Buying Trend Redu..
MT
01/15ARENA PHARMACEUTICALS : ARNA) sees Significant Insider Selling Continuing
MT
01/14INSIDER TRENDS : Arena Pharmaceuticals Insider Sale Scales Back 90-Days of Buys
MT
01/11INSIDER TRENDS : Arena Pharmaceuticals Insider Exercises Option/Derivative Secur..
MT
01/11ARENA PHARMACEUTICALS INC : Regulation FD Disclosure, Financial Statements and E..
AQ
2020ARENA PHARMACEUTICALS : to Present at the J.P. Morgan Healthcare Conference on J..
PR
2020ARENA PHARMACEUTICALS : Reports Inducement Grants under Nasdaq Listing Rule 5635..
AQ
2020ARENA PHARMACEUTICALS : Reports Inducement Grants Under Nasdaq Listing Rule 5635..
PR
2020ARENA PHARMACEUTICALS : to Present Data from the Phase 2b ADVISE Trial Late-Brea..
AQ
2020ARENA PHARMACEUTICALS : to Present Data from the Phase 2b ADVISE Trial - Late-Br..
PR
2020INSIDER TRENDS : Insider Disposition Eases Back 90-Day Buy Trend at Arena Pharma..
MT
2020Arena Pharmaceuticals Reaches Target Enrollment for Phase 3 Trial of Etrasimo..
MT
2020ARENA PHARMACEUTICALS : Achieves Target Enrollment for Etrasimod Phase 3 ELEVATE..
PR
2020INSIDER TRENDS : 90-Day Insider Buying Trend Reduced with Disposition of Arena P..
MT
More news
News in other languages on ARENA PHARMACEUTICALS, INC.

- No features available -

More news
Analyst Recommendations on ARENA PHARMACEUTICALS, INC.
More recommendations
Chart ARENA PHARMACEUTICALS, INC.
Duration : Period :
Arena Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARENA PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Average target price 94,79 $
Last Close Price 77,68 $
Spread / Highest target 49,3%
Spread / Average Target 22,0%
Spread / Lowest Target -2,16%
EPS Revisions
Managers and Directors
NameTitle
Amit Dilip Munshi President, Chief Executive Officer & Director
Tina Susan Nova Chairman
Laurie D. Stelzer Chief Financial Officer & Executive Vice President
Douglas A. Bakan Vice President-Technical Operations
Paul D. Streck Chief Medical Officer & SVP-Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
ARENA PHARMACEUTICALS, INC.1.11%4 518
MODERNA, INC.25.41%51 846
LONZA GROUP AG5.34%50 271
CELLTRION, INC.-13.65%38 245
IQVIA HOLDINGS INC.3.58%35 582
SEAGEN INC.4.35%33 059